FDA Highlights Manufacturing Expectations in Final Potency Guidance

FDA Highlights Manufacturing Expectations in Final Potency Guidance

FDA released final guidance Monday explaining how developers of cell-based and gene-based treatments should demonstrate potency, meaning the biological activity a treatment needs to have its intended effect. Developers should start checking potency early during development and keep checking as manufacturing continues following FDA approval. Those checks help make sure treatments work as intended, and developers need to account for differences from batch to batch, including for treatments made for just one patient.

Potency Assurance Reaches Beyond a Final Test

These therapies use cells or genetic material to treat patients. Potency means a product’s ability to have the treatment effect it is meant to have; testing helps manufacturers check that its biological activity is what they expect. FDA’s advice applies both to products under study and to products that already have a license.

Karim Mikhail linked the guidance to patients with severe illnesses, including cancer and rare diseases, in his role as director of the Center for Biologics Evaluation and Research (CBER). Those patients need to be able to trust that their treatment can do what it is supposed to do. FDA also says that making manufacturing expectations clearer can help people with few treatment options get access sooner.

The final guidance takes the place of earlier advice and goes into more detail on several topics.

TimingRegulatory development
MondayFDA issued its final guidance
December 2023FDA issued the draft
2011Earlier potency-testing guidance now replaced

There is more detail on how companies can make potency assurance part of their existing quality systems, assess risks and get feedback from regulators. FDA also included more examples and changed some of the terms it uses. For developers, the main point is that potency needs attention throughout manufacturing. Testing the finished product can provide an important result, but the materials and manufacturing conditions also help determine what a patient receives. So the guidance matters to teams planning the development pipeline, not just those responsible for quality.

Potency Evidence Needs to Grow During Development

An investigational new drug submission, known as an IND, gives FDA information to assess the clinical study being proposed. Sponsors need to describe their plans for making sure a product is potent enough, and provide enough detail about chemistry, manufacturing and controls. FDA expects those details to grow as development progresses and clinical testing gets broader. Sponsors also need data during clinical development showing how long both the drug substance and the finished product will stay suitable for use. Potency checks included in stability testing for finished products should reflect how far development has progressed.

FDA may put a study on hold when missing potency information prevents FDA from assessing risks for participants. For studies in Phase 2 and Phase 3, FDA can also impose a hold when the study design is not adequate to meet the aims set out for the investigation.

Point in developmentWhat FDA expects
IND filingExplain plans for making sure potency is adequate
Phase 2 and Phase 3Give participants batches potent enough to deliver the intended effect
Biologics license application, or BLAShow that safety, purity and potency will last for the proposed shelf-life period

A sponsor seeking approval of a biological product files a biologics license application, known as a BLA. FDA expects a potency test for each batch after manufacturers finish every production step that might affect potency, although FDA may accept another method if that method offers the same or greater confidence about potency. Companies also have to review changes in manufacturing and determine whether those changes harm potency in a way that could undermine safety or effectiveness.

For drug companies, questions about manufacturing can affect whether a clinical study produces useful findings. If the batches administered to participants have potency that is not known or is poorly controlled, the study might not give companies the information they need to keep potency consistent after approval. Batches that are not potent enough might also fail to deliver the treatment effect they are supposed to produce. Those problems can create difficulties for a development pipeline before the clinical findings are ready for interpretation.

Materials and Manufacturing Checks Shape the Treatment Patients Receive

FDA said companies need to make several choices about manufacturing and carry out checks to help ensure treatments have the required potency. Those choices and checks include:

  • How companies set up the manufacturing process and how companies qualify it.
  • The materials companies choose when making a treatment.
  • Product containers and their closures, along with delivery devices and any other equipment that touches a treatment.
  • Controls that companies use during manufacturing.
  • Potency tests that are suitable, along with testing criteria that fit the treatment’s stage of development.

FDA discusses these measures under CGMP, which sets requirements for manufacturing quality. The guidance also covers treatments that cannot be stored for long, treatments made for individual patients and gene therapies delivered using viral vectors, which carry genetic material. FDA said sponsors should use what they have learned from similar products. Sponsors can learn more through nonclinical research, through studies of how a treatment works and through examining product characteristics connected with potency, and FDA also discusses finding the manufacturing conditions that affect those characteristics. Assessing risks can show companies where they need controls. FDA recommends building up the potency assurance strategy as a treatment moves through development, and FDA encourages sponsors to ask regulators for feedback early on the overall strategy and the tests used to measure potency.

For hospitals and patients, the question is whether they can rely on the treatment that is actually given. Whether a treatment works as intended depends in part on having the biological activity it needs when it is given to patients. The guidance puts more attention on that issue while treatments are being developed and manufactured. That does not mean the guidance, by itself, shows that treatment outcomes will improve or that patients will receive treatments any sooner.

Questions About FDA’s Guidance

When Did FDA Release the Guidance?

FDA released its final guidance Monday, after publishing a draft in December 2023. The guidance takes the place of FDA’s 2011 document on potency testing.

Which Sponsors Are Covered?

The guidance covers sponsors developing cell therapies and gene therapies, both those still being studied and those already licensed. FDA also discusses treatments made for individual patients, treatments that have short shelf lives and gene therapies made with viral vectors.

What Do Sponsors Need to Demonstrate for Approval?

Sponsors seeking a BLA need to demonstrate that a product is safe, potent and pure, and that it will retain those qualities for its full shelf life. Sponsors generally need to check every batch for potency after completing any manufacturing steps that might affect potency. FDA can accept another approach, but that approach needs to provide at least as much assurance about potency.

What Should Sponsors Do While Development Moves Ahead?

FDA encourages sponsors to speak with regulators early about their plans for assuring potency and the tests they plan to use, and sponsors should provide more information supporting those plans as development moves ahead. FDA can place a study on clinical hold if missing potency information means FDA cannot assess the risks to people participating in the study.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later